Monthly Archives: July 2014

Discovery may make it easier to develop life-saving stem cells

Posted: July 18, 2014 at 10:48 pm

PUBLIC RELEASE DATE:

17-Jul-2014

Contact: Tom Oswald tom.oswald@cabs.msu.edu 517-432-0920 Michigan State University

Not unlike looking for the proverbial needle in a haystack, a team of Michigan State University researchers have found a gene that could be key to the development of stem cells cells that can potentially save millions of lives by morphing into practically any cell in the body.

The gene, known as ASF1A, was not discovered by the team. However, it is at least one of the genes responsible for the mechanism of cellular reprogramming, a phenomenon that can turn one cell type into another, which is key to the making of stem cells.

In a paper published in the journal Science, the researchers describe how they analyzed more than 5,000 genes from a human egg, or oocyte, before determining that the ASF1A, along with another gene known as OCT4 and a helper soluble molecule, were the ones responsible for the reprogramming.

"This has the potential to be a major breakthrough in the way we look at how stem cells are developed," said Elena Gonzalez-Munoz, a former MSU post-doctoral researcher and first author of the paper. "Researchers are just now figuring out how adult somatic cells such as skin cells can be turned into embryonic stem cells. Hopefully this will be the way to understand more about how that mechanism works."

In 2006, an MSU team identified the thousands of genes that reside in the oocyte. It was from those, they concluded, that they could identify the genes responsible for cellular reprogramming.

In 2007, a team of Japanese researchers found that by introducing four other genes into cells, stem cells could be created without the use of a human egg. These cells are called induced pluripotent stem cells, or iPSCs.

"This is important because the iPSCs are derived directly from adult tissue and can be a perfect genetic match for a patient," said Jose Cibelli, an MSU professor of animal science and a member of the team.

Link:
Discovery may make it easier to develop life-saving stem cells

Posted in Stem Cells | Comments Off on Discovery may make it easier to develop life-saving stem cells

Global Market for Induced Pluripotent Stem Cells to Reach $2.9 Billion in 2018; Technology Offers New Hope for …

Posted: July 18, 2014 at 10:48 pm

(PRWEB) July 17, 2014

BCC Research (http://www.bccresearch.com) reveals in its new report, INDUCED PLURIPOTENT STEM CELLS: GLOBAL MARKETS, the global market for induced pluripotent stem cells (iPSCs) is expected to grow to $2.9 billion by 2018, with a five-year compound annual growth rate (CAGR) of 19.7%. The Asia-Pacific market, the fastest performing regional segment, is projected to move at a significant CAGR of 22%.

iPSCs are a breakthrough technology recognized by the 2012 Nobel Physiology and Medicine Prize. They are expected to bring revolutionary changes to modern medicine and new hope for reprogramming cells to repair damaged tissues in the human body. They are already useful for drug development and modeling of diseases; scientists hope to use them as powerful tools in tissue transplants since they can be developed from a patient's own cells, avoiding the risk of rejection that is often encountered. The technologies of differentiating iPSCs into various tissue cells are also developing rapidly.

Markets and applications for this technology include academic research, drug development and toxicity testing, regenerative medicine, molecular and cellular engineering, cellular reprogramming, and cell culture.

"The clinical research and service iPSCs market is expected to experience rapid growth in the next few years," says BCC Research biotechnology analyst Mike Fan. "Indeed, iPSCs technology is speeding up and improving the drug discovery process, particularly in promoting personal medicine and the development of personalized drugs and diagnostic tests."

iPSCs are artificially derived from non-pluripotent somatic cells by inducing expression of specific genes. Similar to embryonic stem cells, iPSCs possess pluripotency but reduce associated ethical issues by eliminating the use of embryos. Pluripotency refers to the ability to become any tissue in the body, excluding a placenta.

INDUCED PLURIPOTENT STEM CELLS: GLOBAL MARKETS provides an overview of the global market for iPSCs. It includes analyses of global market trends, with data from 2012 and 2013, and projections of CAGRs through 2018, as well as profiles of companies important in the industry.

Editors and reporters, who wish to speak with the analyst, should contact Steven Cumming at steven.cumming(at)bccresearch(dot)com.

About BCC Research

BCC Research publishes market research reports that make organizations worldwide more profitable with intelligence that drives smart business decisions. These reports cover today's major industrial and technology sectors, including emerging markets. For more than 40 years, we have helped customers identify new market opportunities with accurate and reliable data and insight, including market sizing, forecasting, industry overviews, and identification of significant trends and key competitors. We partner with analysts who are experts in specific areas of industry and technology, providing unbiased measurements and assessments of global markets. Our clients include the top companies in industries around the world as well as universities, business schools, start-ups, consulting firms and investment companies. BCC Research is a unit of Eli Research LLC. Visit our website at http://www.bccresearch.com. Contact us: (+1) 781-489-7301 (U.S. Eastern Time), or email information(at)bccresearch(dot)com.

View original post here:
Global Market for Induced Pluripotent Stem Cells to Reach $2.9 Billion in 2018; Technology Offers New Hope for ...

Posted in Stem Cells | Comments Off on Global Market for Induced Pluripotent Stem Cells to Reach $2.9 Billion in 2018; Technology Offers New Hope for …

'Support' cells in brain play important role in Down syndrome

Posted: July 18, 2014 at 10:46 pm

PUBLIC RELEASE DATE:

18-Jul-2014

Contact: Charles Casey charles.casey@ucdmc.ucdavis.edu 916-734-9048 University of California - Davis Health System

(SACRAMENTO, Calif.) Researchers from UC Davis School of Medicine and Shriners Hospitals for Children Northern California have identified a group of cells in the brain that they say plays an important role in the abnormal neuron development in Down syndrome. After developing a new model for studying the syndrome using patient-derived stem cells, the scientists also found that applying an inexpensive antibiotic to the cells appears to correct many abnormalities in the interaction between the cells and developing neurons.

The findings, which focused on support cells in the brain called astroglial cells, appear online today in Nature Communications.

"We have developed a human cellular model for studying brain development in Down syndrome that allows us to carry out detailed physiological studies and screen possible new therapies," said Wenbin Deng, associate professor of biochemistry and molecular medicine and principal investigator of the study. "This model is more realistic than traditional animal models because it is derived from a patient's own cells."

Down syndrome is the most common chromosomal cause of mild to moderate intellectual disabilities in the United States, where it occurs in one in every 691 live births. It develops when a person has three copies of the 21st chromosome instead of the normal two. While mouse models have traditionally been used in studying the genetic disorder, Deng said the animal model is inadequate because the human brain is more complicated, and much of that complexity arises from astroglia cells, the star-shaped cells that play an important role in the physical structure of the brain as well as in the transmission of nerve impulses.

"Although neurons are regarded as our 'thinking cells,' the astroglia have an extremely important supportive role," said Deng. "Astroglial function is increasingly recognized as a critical factor in neuronal dysfunction in the brain, and this is the first study to show its importance in Down syndrome."

Creating a unique human cellular model

To investigate the role of astroglia in Down syndrome, the research team took skin cells from individuals with Down syndrome and transformed them into stem cells, which are known as induced pluripotent stem cells (iPSC). The cells possess the same genetic make-up as the donor and an ability to grow into different cell types. Deng and his colleagues next induced the stem cells to develop into separate pure populations of astroglial cells and neurons. This allowed them to systematically analyze factors expressed by the astroglia and then study their effects on neuron development.

Read the original:
'Support' cells in brain play important role in Down syndrome

Posted in Genetic medicine | Comments Off on 'Support' cells in brain play important role in Down syndrome

International research team discovers genetic dysfunction connected to hydrocephalus

Posted: July 18, 2014 at 10:46 pm

PUBLIC RELEASE DATE:

17-Jul-2014

Contact: Jeannette Spalding jeannette.spalding@case.edu 216-368-3004 Case Western Reserve University

The mysterious condition once known as "water on the brain" became just a bit less murky this week thanks to a global research group led in part by a Case Western Reserve researcher. Professor Anthony Wynshaw-Boris, MD, PhD, is the co-principal investigator on a study that illustrates how the domino effect of one genetic error can contribute to excessive cerebrospinal fluid surrounding the brains of mice a disorder known as hydrocephalus. The findings appear online July 17 in the journal Neuron.

Cerebrospinal fluid provides a cushion between the organ and the skull, eliminating waste and performing other functions essential to neurological health. Within the brain there are four spaces or ventricles where cerebrospinal fluid flows. Hydrocephalus can be damaging when excessive cerebrospinal fluid widens spaces between ventricles and creates pressure to brain tissue. In humans, hydrocephalus can cause a host of neurological ailments: impairment of balance and coordination, memory loss, headaches and blurred vision, and even damage to the brain.

"Most of the time, hydrocephalus is caused by some sort of physical blockage of the flow of cerebrospinal fluid, so called obstructive hydrocephalus. We demonstrated instead that malfunction of specific genes the Dishevelleds (Dvl genes) triggered hydrocephalus in our mouse models. These genes regulate the precise placement and alignment of cilia within ependymal cells that move cerebrospinal fluid throughout the brain," said Wynshaw-Boris, MD, PhD, James H. Jewell MD '34 Professor of Genetics and Chair, Department of Genetics and Genome Sciences, Case Western Reserve University School of Medicine. "This discovery paves the way for more focused research to determine if similar mechanisms can cause hydrocephalus in humans."

Scientists are still at the most nascent stages of understanding different causes and kinds of hydrocephalus. In some instances, the root sources are genetic; in others, the fluid accumulation is attributed to complications of premature birth. This project illuminates one way in which genetic influences contribute to the condition.

Wynshaw-Boris began this collaborative research while a professor in pediatrics at the Institute for Human Genetics and the Eli and Edythe Broad Center of Regeneration Medicine and Stem Cell Research at the University of California at San Francisco (UCSF) before coming to Case Western Reserve in June 2013. For this hydrocephalus project, he joined fellow principal co-investigator, Arturo Alvarez-Buylla, PhD, professor of neurological surgery, and the Heather and Melanie Muss Endowed Chair, Department of Neurological Surgery, UCSF, in conducting research that proved in mice that Dvl genes regulate the placement and polarity of cilia in ependymal cells that line the ventricles of the brain.

A cilium is a slender protuberance projecting from many cells. In the ependymal cells, multiple cilia protrude from each cell as a bundle or patch, which resembles a horse's tail when beating to move cerebrospinal fluid efficiently. Each cilium must be anchored, sized and shaped correctly, properly placed and aligned in relation to other cilia within the same cell, and the alignment of cilia between cells is also necessary so that the cilia beat with precision to achieve proper movement of fluid in the right direction. It is all about excellent organization: the wrong size, shape or angle of rotation of the bundle of cilia will impede the smooth and appropriate directional flow of the cerebrospinal fluid.

The work in mice by Shinya Ohata, PhD, and Jin Nakatani, PhD, co-first authors who worked in the Alvarez-Buylla and Wynshaw-Boris labs, respectively, and their colleagues demonstrated how normal versus Dvl-deficient mice fared in terms of cilia function. They examined cilia from the ependymal cells of normal mice and found the cilia to be well organized and correctly placed within and between ependymal cells. Investigators even viewed in real time through fluorescent imaging the intricacy with which well-orchestrated cilia swayed to move fluid along in a normal fashion.

View original post here:
International research team discovers genetic dysfunction connected to hydrocephalus

Posted in Genetic medicine | Comments Off on International research team discovers genetic dysfunction connected to hydrocephalus

Scientists use gene therapy to create biological pacemaker

Posted: July 18, 2014 at 10:46 pm

Washington No batteries required: Scientists are creating a biological pacemaker by injecting a gene into the hearts of sick pigs that changed ordinary cardiac cells into a special kind that induces a steady heartbeat.

The study, published Wednesday, is one step toward developing an alternative to electronic pacemakers that are implanted into 300,000 Americans a year.

There are people who desperately need a pacemaker but cant get one safely, said Dr. Eduardo Marban, director of the Cedars-Sinai Heart Institute in Los Angeles, who led the work. This development heralds a new era of gene therapy that one day might offer them an option.

Your heartbeat depends on a natural pacemaker, a small cluster of cells its about the size of a peppercorn, Marban says that generates electrical activity. Called the sinoatrial node, it acts like a metronome to keep the heart pulsing at 60 to 100 beats a minute or so, more when youre active. If that node quits working correctly, hooking the heart to an electronic pacemaker works very well for most people.

But about 2 percent of recipients develop an infection that requires the pacemaker to be removed for weeks until antibiotics wipe out the germs, Marban said. And some fetuses are at risk of stillbirth when their heartbeat falters, a condition called congenital heart block.

For over a decade, teams of researchers have worked to create a biological alternative that might help those kinds of patients, trying such approaches as using stem cells to spur the growth of a new sinoatrial node.

Marbans newest attempt uses gene therapy to reprogram a small number of existing heart muscle cells so that they start looking and acting like natural pacemaker cells instead.

Because pigs hearts are so similar to human hearts, Marbans team studied the approach in 12 laboratory pigs with a defective heart rhythm.

They used a gene named TBX18 that plays a role in the embryonic development of the sinoatrial node. Working through a vein, they injected the gene into some of the pigs hearts in a spot that doesnt normally initiate heartbeats and tracked them for two weeks.

Two days later, treated pigs had faster heartbeats than control pigs who didnt receive the gene, the researchers reported in the journal Science Translational Medicine. That heart rate automatically fluctuated, faster during the day. The treated animals also became more active, without signs of side effects.

Excerpt from:
Scientists use gene therapy to create biological pacemaker

Posted in Gene therapy | Comments Off on Scientists use gene therapy to create biological pacemaker

Scientists using gene therapy to create biological pacemaker

Posted: July 18, 2014 at 10:46 pm

WASHINGTON --

The study, published Wednesday, is one step toward developing an alternative to electronic pacemakers that are implanted into 300,000 Americans a year.

"There are people who desperately need a pacemaker but can't get one safely," said Dr. Eduardo Marban, director of the Cedars-Sinai Heart Institute in Los Angeles, who led the work. "This development heralds a new era of gene therapy" that one day might offer them an option.

Your heartbeat depends on a natural pacemaker, a small cluster of cells - it's about the size of a peppercorn, Marban says - that generates electrical activity. Called the sinoatrial node, it acts like a metronome to keep the heart pulsing at 60 to 100 beats a minute or so, more when you're active. If that node quits working correctly, hooking the heart to an electronic pacemaker works very well for most people.

But about 2 percent of recipients develop an infection that requires the pacemaker to be removed for weeks until antibiotics wipe out the germs, Marban said. And some fetuses are at risk of stillbirth when their heartbeat falters, a condition called congenital heart block.

For over a decade, teams of researchers have worked to create a biological alternative that might help those kinds of patients, trying such approaches as using stem cells to spur the growth of a new sinoatrial node.

Marban's newest attempt uses gene therapy to reprogram a small number of existing heart muscle cells so that they start looking and acting like natural pacemaker cells instead.

Because pigs' hearts are so similar to human hearts, Marban's team studied the approach in 12 laboratory pigs with a defective heart rhythm.

They used a gene named TBX18 that plays a role in the embryonic development of the sinoatrial node. Working through a vein, they injected the gene into some of the pigs' hearts - in a spot that doesn't normally initiate heartbeats - and tracked them for two weeks.

Two days later, treated pigs had faster heartbeats than control pigs who didn't receive the gene, the researchers reported in the journal Science Translational Medicine. That heart rate automatically fluctuated, faster during the day. The treated animals also became more active, without signs of side effects.

More:
Scientists using gene therapy to create biological pacemaker

Posted in Gene therapy | Comments Off on Scientists using gene therapy to create biological pacemaker

DR ANDREW J ROCHMAN: ON STEM CELL THERAPY – Video

Posted: July 18, 2014 at 10:40 pm


DR ANDREW J ROCHMAN: ON STEM CELL THERAPY

By: Len Promoter

Continued here:
DR ANDREW J ROCHMAN: ON STEM CELL THERAPY - Video

Posted in Cell Therapy, Stem Cell Therapy | Comments Off on DR ANDREW J ROCHMAN: ON STEM CELL THERAPY – Video

I-DNA Phyto Stem Cell Therapy Miracle – Lily Khoo Testimonial – Video

Posted: July 18, 2014 at 10:40 pm


I-DNA Phyto Stem Cell Therapy Miracle - Lily Khoo Testimonial
3 3 weeks, improving eye sight, skin tightening, solving triangular eyes...

By: I-DNA DEER PLACENTA SINGAPORE ORIGINAL

Follow this link:
I-DNA Phyto Stem Cell Therapy Miracle - Lily Khoo Testimonial - Video

Posted in Cell Therapy, Stem Cell Therapy | Comments Off on I-DNA Phyto Stem Cell Therapy Miracle – Lily Khoo Testimonial – Video

Diabetes stem cell therapy readied

Posted: July 18, 2014 at 10:40 pm

Paul Laikind, CEO of ViaCyte, which is making a treatment for diabetes from human embryonic stem cells.

In an historic announcement for the stem cell field, San Diego's ViaCyte said Thursday it has applied to start human clinical trials of its treatment for Type 1 diabetes.

ViaCyte grows replacement insulin-producing cells from human embryonic stem cells. The cells are packaged while maturing in a semi-permeable device and implanted. In animal trials, the cells produce insulin, relieving diabetes.

Now the company proposes to take what could be a cure for diabetes into people. ViaCyte has asked to begin a Phase 1/2 clinical trial, which would assess both safety and efficacy of its product. ViaCyte is targeting Type 1 diabetes, in which the insulin-producing cells are destroyed. Patients require multiple injections of insulin daily to survive.

The announcement is good news for California's stem cell agency, the California Institute for Regenerative Medicine. The agency has awarded nearly $39 million to ViaCyte to ready its device for human use.

Paul Laikind, ViaCytes chief executive, said if all goes smoothly, the first patients will be treated in August or September. Based on animal studies, it will take a few months to see results, and just a few patients will be treated at first.

CIRM itself, funded with $3 billion in state bond funds, has come under pressure to show results from its work. The money is projected to run out in 2017. Some supporters of the agency have proposed launching a new initiative to continue funding.

"This is a great example of how the investment that the voters made in creating CIRM is beginning to move from labs to patients," said Joe Panetta, a member of CIRM's governing board and chief executive of Biocom, the San Diego-based life science trade group. ""There are at least a dozen other clinical trials in progress. This is good for CIRM and San Diego."

Jonathan Thomas, chairman of CIRM's governing board, called the filing "a big step in developing therapies for Type 1 diabetes."

"The project is one that has been front and center for us for six years," Thomas said. "As a principal funder of Viacyte since 2008, we are delighted that they have taken this major step towards getting a Type 1 Diabetes therapy to patients."

More:
Diabetes stem cell therapy readied

Posted in Cell Therapy, Stem Cell Therapy | Comments Off on Diabetes stem cell therapy readied

Arizona Pet Vet, a Family of Animal Hospitals in Central Arizona, is Hosting Vet-Stem, Inc. for Continued Education …

Posted: July 18, 2014 at 10:40 pm

Phoenix, AZ (PRWEB) July 17, 2014

Arizona Pet Vet Family of Animal Hospitals is hosting San Diego, California based Regenerative Veterinary Medicine company, Vet-Stem, Inc., for a summer session of RACE approved Credentialing Courses and wet-labs on stem cell therapy. AZ Pet Vets Family of 17 Animal Hospitals has been offering Vet-Stems Regenerative Cell Therapy to its small animal patients since 2010, and continuously strives to educate their team members on cutting-edge services like stem cell therapy.

Since Vet-Stems last training session with AZ Pet Vet in the summer of 2013 the number of pets diagnosed with arthritis has increased as much as an estimated 13% say industry sources. As many as 65% of dogs between the ages of 7 and 11 years old will be inflicted with some degree of arthritis. For certain specific breeds the percentage is as high as 70%, with an additional estimated 7% remaining undiagnosed. AZ Pet Vets Family of Animal Hospitals equips their veterinarians with a complete package of services to help diagnose and treat dogs that are suffering pain or inflammation from osteoarthritis or polyarthritis. Stem cell therapy is one of these services, most commonly used to help decrease inflammation, help with the pain of osteo or polyarthritis, as well as other joint or ligament issues, and muscle injuries.

Vet-Stems Corey Orava, DVM will be leading a series of daily training sessions which include a RACE (Registry of Approved Continuing Education from the American Association of Veterinary State Boards) approved credentialing course, and the ability to consult on potential stem cell therapy cases with current patients of AZ Pet Vets Family of Animal Hospitals. Each of these sessions will help veterinarians and their staff to learn the ins and outs of stem cell therapy, as well as benefit from a hands-on experience to bring the best care to their patients and pet owners. Under the mentorship of Dr. Orava all of the 17 AZ Pet Vet Animal Hospitals will have the potential to collect fat and inject stem cells on qualifying pet patients.

AZ Pet Vet is a family of 17 animal hospitals with one vision: to provide the best comprehensive care for their highly valued patients. Whether it be routine wellness, or other type of medical care, AZ Pet Vet provides loving care and treatment for pets. As animal lovers and pet owners, they understand the connection owners have with your pet. The doctors and staff at each hospital strive to build a long term relationship with their client families and their pets, always making recommendations in the pets best health interest. The AZ Pet Vet Family of Animal Hospitals offer complete veterinary care from wellness, to vaccines, spays and neuters, dental, surgical and now regenerative medicine. Their animal hospital locations can be easily found at http://www.arizonapetvet.com/.

Since its formation in 2002, Vet-Stem, Inc. has endeavored to improve the lives of animals through regenerative medicine. As the first company in the United States to provide an adipose-derived stem cell service to veterinarians for their patients, Vet-Stem pioneered the use of regenerative stem cells for horses, dogs, cats, and some exotics. In 2004 the first horse was treated with Vet-Stem Regenerative Cell Therapy for a tendon injury that would normally have been career ending. Ten years later Vet-Stem celebrated its 10,000th animal treated, and the success of establishing stem cell therapy as a proven regenerative medicine for certain inflammatory, degenerative, and arthritic diseases. As animal advocates, veterinarians, veterinary technicians, and cell biologists, the team at Vet-Stem tasks themselves with the responsibility of discovering, refining, and bringing to market innovative medical therapies that utilize the bodys own healing and regenerative cells. For more information about Vet-Stem and Regenerative Veterinary Medicine, visit http://www.vet-stem.com or call 858-748-2004.

View post:
Arizona Pet Vet, a Family of Animal Hospitals in Central Arizona, is Hosting Vet-Stem, Inc. for Continued Education ...

Posted in Cell Therapy, Stem Cell Therapy | Comments Off on Arizona Pet Vet, a Family of Animal Hospitals in Central Arizona, is Hosting Vet-Stem, Inc. for Continued Education …